Irinotecan Interactions

Coadministration is contraindicated. Itraconazole increases plasma concentrations, potentially increasing pharmacologic effects and adverse reactions.

Source: NLP:itraconazole

Coadministration of ketoconazole with irinotecan is contraindicated.

Source: NLP:ketoconazole

BCRP substrate (SN-38 metabolite); eltrombopag may increase exposure. Monitor closely for excessive drug exposure.

Source: NLP:eltrombopag

BCRP substrate (active metabolite SN-38); monitor for excessive exposure and consider dose reduction if appropriate.

Source: NLP:eltrombopag olamine

Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.

Source: NLP:netupitant and palonosetron

Increased plasma concentrations may result in potential adverse reactions. Monitor for adverse reactions if use cannot be avoided.

Source: NLP:rolapitant

No clinically meaningful effect on irinotecan pharmacokinetics observed when administered with bevacizumab.

Source: NLP:bevacizumab-awwb